← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rubicon Biotechnology, Inc.
Irvine, CA
$1,397,888
Total funding
4
Grants
Funding over time
peak $573.5K · FY2013–17$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,397,888 · 4
By mechanism
R43$728,788 · 3
R21$669,100 · 1
Investigators at Rubicon Biotechnology, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalation$318,914
R21 · FY2013 · ES
Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalation$300,186
R21 · FY2014 · ES
Modified Annexin V for immunostimulation of the tumor microenvironment$292,989
R43 · FY2015 · CA
Intracellular targeting Hsp70 for myocardial cytoprotection after an infarction$223,333
R43 · FY2014 · HL
Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion$212,466
R43 · FY2017 · EY
Intracellular targeting Hsp70 for pulmonary cytoprotection after toxin inhalation$50,000
R21 · FY2014 · ES